The Journal of Experimental Medicine
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Latest Articles
Published online
doi:10.1084/jem.20061196
The Journal of Experimental Medicine
The Rockefeller University Press, 0022-1007 $30.00
© Hammad et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 4614K)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hammad, H.
Right arrow Articles by Lambrecht, B. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hammad, H.
Right arrow Articles by Lambrecht, B. N.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ARTICLE

 Activation of the D prostanoid 1 receptor suppresses asthma by modulation of lung dendritic cell function and induction of regulatory T cells

Hamida Hammad1, Mirjam Kool1, Thomas Soullié1, Shuh Narumiya2, François Trottein3, Henk C. Hoogsteden1, and Bart N. Lambrecht1

1 Department of Pulmonary Medicine, Erasmus Medical Center, 3015 GE Rotterdam, Netherlands
2 Department of Pharmacology, Faculty of Medicine, Kyoto University, Kyoto 606-8501, Japan
3 Institut National de la Santé et de la Recherche Médicale, Unit 547, Institut Pasteur de Lille, Lille 59019, France

CORRESPONDENCE Bart N. Lambrecht: b.lambrecht{at}erasmusmc.nl

Prostaglandins (PGs) can enhance or suppress inflammation by acting on different receptors expressed by hematopoietic and nonhematopoietic cells. Prostaglandin D2 binds to the D prostanoid (DP)1 and DP2 receptor and is seen as a critical mediator of asthma causing vasodilation, bronchoconstriction, and inflammatory cell influx. Here we show that inhalation of a selective DP1 agonist suppresses the cardinal features of asthma by targeting the function of lung dendritic cells (DCs). In mice treated with DP1 agonist or receiving DP1 agonist-treated DCs, there was an increase in Foxp3+ CD4+ regulatory T cells that suppressed inflammation in an interleukin 10–dependent way. These effects of DP1 agonist on DCs were mediated by cyclic AMP–dependent protein kinase A. We furthermore show that activation of DP1 by an endogenous ligand inhibits airway inflammation as chimeric mice with selective hematopoietic loss of DP1 had strongly enhanced airway inflammation and antigen-pulsed DCs lacking DP1 were better at inducing airway T helper 2 responses in the lung. Triggering DP1 on DCs is an important mechanism to induce regulatory T cells and to control the extent of airway inflammation. This pathway could be exploited to design novel treatments for asthma.

Abbreviations used: BAL, bronchoalveolar lavage; BHR, bronchial hyperresponsiveness; COX, cyclooxygenase; DP, D prostanoid; EP, E prostanoid; i.t., intratracheal; mDC, myeloid DC; MHC, metacholine; MLN, mediastinal LN; pDC, plasmacytoid DC; PenH, enhanced pause; PG, prostaglandin; PGD2, prostaglandin D2; PGE2, prostaglandin E2; PKA, protein kinase A.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search